BR112023007922A2 - METHOD OF GENERATING TUMOR INFILTRATING LYMPHOCYTES, METHOD OF EXPANDING A POPULATION OF TUMOR INFILTRATING LYMPHOCYTES (TILS) OR MARROW INFILTRATING LYMPHOCYTES (MILS) AND METHODS OF TREATMENT OF CANCER IN A SUBJECT - Google Patents

METHOD OF GENERATING TUMOR INFILTRATING LYMPHOCYTES, METHOD OF EXPANDING A POPULATION OF TUMOR INFILTRATING LYMPHOCYTES (TILS) OR MARROW INFILTRATING LYMPHOCYTES (MILS) AND METHODS OF TREATMENT OF CANCER IN A SUBJECT

Info

Publication number
BR112023007922A2
BR112023007922A2 BR112023007922A BR112023007922A BR112023007922A2 BR 112023007922 A2 BR112023007922 A2 BR 112023007922A2 BR 112023007922 A BR112023007922 A BR 112023007922A BR 112023007922 A BR112023007922 A BR 112023007922A BR 112023007922 A2 BR112023007922 A2 BR 112023007922A2
Authority
BR
Brazil
Prior art keywords
infiltrating lymphocytes
tumor infiltrating
methods
expanding
population
Prior art date
Application number
BR112023007922A
Other languages
Portuguese (pt)
Inventor
Amer Beg
J Cantwell Mark
Original Assignee
H Lee Moffitt Cancer Ct & Res
Memgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H Lee Moffitt Cancer Ct & Res, Memgen Inc filed Critical H Lee Moffitt Cancer Ct & Res
Publication of BR112023007922A2 publication Critical patent/BR112023007922A2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/761—Adenovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Plant Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

método de geração de linfócitos infiltrantes no tumor, método para expandir uma população de linfócitos infiltrantes no tumor (tils) ou linfócitos infiltrantes na medula (mils) e métodos de tratamento de câncer em um sujeito. são divulgados métodos para expandir populações de linfócitos infiltrantes de tumor (til) e métodos de uso da população de til expandida para tratamento de câncer.method of generating tumor-infiltrating lymphocytes, method of expanding a population of tumor-infiltrating lymphocytes (tils) or marrow-infiltrating lymphocytes (mils), and methods of treating cancer in a subject. Methods for expanding tumor-infiltrating lymphocyte (TIL) populations and methods of using the expanded TIL population for treating cancer are disclosed.

BR112023007922A 2020-10-27 2021-10-27 METHOD OF GENERATING TUMOR INFILTRATING LYMPHOCYTES, METHOD OF EXPANDING A POPULATION OF TUMOR INFILTRATING LYMPHOCYTES (TILS) OR MARROW INFILTRATING LYMPHOCYTES (MILS) AND METHODS OF TREATMENT OF CANCER IN A SUBJECT BR112023007922A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063106215P 2020-10-27 2020-10-27
PCT/US2021/056829 WO2022093944A2 (en) 2020-10-27 2021-10-27 Oncolytic virus boosts t cell response for effective til therapy

Publications (1)

Publication Number Publication Date
BR112023007922A2 true BR112023007922A2 (en) 2023-10-03

Family

ID=81384494

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023007922A BR112023007922A2 (en) 2020-10-27 2021-10-27 METHOD OF GENERATING TUMOR INFILTRATING LYMPHOCYTES, METHOD OF EXPANDING A POPULATION OF TUMOR INFILTRATING LYMPHOCYTES (TILS) OR MARROW INFILTRATING LYMPHOCYTES (MILS) AND METHODS OF TREATMENT OF CANCER IN A SUBJECT

Country Status (8)

Country Link
EP (1) EP4237566A2 (en)
JP (1) JP2023548831A (en)
CN (1) CN116710564A (en)
AU (1) AU2021368569A1 (en)
BR (1) BR112023007922A2 (en)
CA (1) CA3196553A1 (en)
MX (1) MX2023004780A (en)
WO (1) WO2022093944A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022170219A1 (en) * 2021-02-05 2022-08-11 Iovance Biotherapeutics, Inc. Adjuvant therapy for cancer
WO2023108003A2 (en) * 2021-12-07 2023-06-15 Memgen, Inc. Oncolytic virus boosts t cell response for effective til therapy
CN116059260A (en) * 2023-03-07 2023-05-05 华南农业大学 Application of SVA virus in preparation of tumor prevention and treatment drugs and anti-tumor composition

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106659913A (en) * 2014-03-20 2017-05-10 H.李莫菲特癌症中心研究院 Tumor-infiltrating lymphocytes for adoptive cell therapy
MX2020013901A (en) * 2018-06-19 2021-05-27 H Lee Moffitt Cancer Ct & Res Oncolytic virus or antigen presenting cell mediated cancer therapy using type i interferon and cd40-ligand.

Also Published As

Publication number Publication date
CA3196553A1 (en) 2022-05-05
CN116710564A (en) 2023-09-05
JP2023548831A (en) 2023-11-21
WO2022093944A3 (en) 2022-07-21
AU2021368569A1 (en) 2023-06-08
WO2022093944A2 (en) 2022-05-05
EP4237566A2 (en) 2023-09-06
MX2023004780A (en) 2023-05-09

Similar Documents

Publication Publication Date Title
BR112023007922A2 (en) METHOD OF GENERATING TUMOR INFILTRATING LYMPHOCYTES, METHOD OF EXPANDING A POPULATION OF TUMOR INFILTRATING LYMPHOCYTES (TILS) OR MARROW INFILTRATING LYMPHOCYTES (MILS) AND METHODS OF TREATMENT OF CANCER IN A SUBJECT
PH12021550805A1 (en) Methods and Compositions for Editing RNAs
BR112019008560A2 (en) artificial antigen-presenting cell, method for expanding tumor infiltrating lymphocytes, treating cancer with a population of tumor infiltrating lymphocytes and for assessing the power of tumor infiltrating lymphocytes, kit, tumor infiltrating lymphocyte population, and, combination
PH12019502528A1 (en) Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof
DE122007000082I1 (en) METHOD FOR THE REPLICATION OF INFLUENZA IN CELL CULTURE AND THE INFLUENZA VIRUSES PRODUCED BY THIS PROCEDURE
BR112019003279A8 (en) SYSTEMS AND METHODS FOR COMPUTER-AID ORTHOGNATIC SURGICAL PLANNING
MX2022000497A (en) Targeted rna editing by leveraging endogenous adar using engineered rnas.
WO2021231237A3 (en) Antibodies for sars-cov-2 and uses thereof
ATE552849T1 (en) TREATMENT METHODS USING CTLA-4 ANTIBODIES
MX2021005353A (en) Compositions, methods and systems for protein corona analysis and uses thereof.
BR0015501A (en) Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immune effect agents
CR20220317A (en) Anti-cd73 antibodies and uses thereof
DK0669133T3 (en) Multipotent paramunity-indicated agents based on combinations of smallpox virus components, methods for their preparation and their use as drugs
DE69731836D1 (en) INDUCTION OF T CELL TOLERANCE USING A SOLUBLE MOLECULAR THAT CAN CREATE TWO COSTIMULATION PATHS AT THE SAME TIME
ATE466079T1 (en) NUCLEIC ACID CONSTRUCTS, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER
BR112022015380A2 (en) COMPOSITIONS AND METHODS FOR EDITING KALLYKREIN GENE (KLKB1)
BR112023002123A2 (en) FC FUSION PROTEIN, ISOLATED NUCLEIC ACIDS, METHOD OF PRODUCING FC FUSION PROTEIN, PHARMACEUTICAL FORMULATION, METHODS FOR EXPANDING THE NUMBER OF DENDRITIC CELLS (DCS) IN AN INDIVIDUAL AND FOR TREATMENT OF CANCER, EFFECTOR-FREE PROTEIN AND ANTI-FCRP
DK1313462T3 (en) Use of Asian acid or asiaticoside for the treatment of cancer
BR112021016875A2 (en) Process for expansion of peripheral blood lymphocytes
BRPI0406037A (en) Meat product or meat analogue containing soy and method for preparing same
CA3156667A1 (en) Oligonucleotides with nucleoside analogs
ES2187648T3 (en) METHOD FOR THE ADMINISTRATION OF PHARMACOS FOR GENE THERAPY.
BR112021021921A2 (en) Agent, use of an agent and method of treating or preventing a metabolic disease
MX2021005564A (en) Methods and compositions for cancer immunotherapy.
BR112019007365A2 (en) methods and compositions for tusc2 immunotherapy